Capecitabine in breast cancer
Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S
Record ID 32005000635
Spanish
Authors' objectives:
This report aims to assess the effectiveness of capecitabine in breast cancer.
Authors' results and conclusions:
The decision about this treatment should be jointly taken by the treating physician(s) and the individual. As the adverse event profile may be less tolerable, the decision has to be made after an informed discussion between parties taking into account contraindications, agent s side effects, alternative therapies as well as patient preferences and medical condition. Capecitabine must be used by oncologists specialized in breast cancer treatment.
Authors' recommendations:
Capecitabine in combination with docetaxel can be a therapeutic alternative when ALL the following criteria are met: 1.Patients with locally advanced or metastatic breast cancer. 2.Patients failed or are not elegible for antracycline containing regimens. It must be taken into account that, up until now, the main evidence about capecitabine comes from one randomized clinical trial which showed a three-month survival improvement. As a single agent therapy, the evidence is of less quality and could be considered as a therapeutic alternative for patients who meet ALL these criteria:
Patients with locally advanced or metastatic breast cancer and one of the following: 3.Patients who have not already received capecitabine as combined therapy and have failed antracycline or taxane regimens; or 4.Patients for whom another antracycline treatment is contraindicated.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.iecs.org.ar/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Female
- Antimetabolites, Antineoplastic
- Breast Neoplasms
- Deoxycytidine
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.